Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.75 CAD | +2.15% | +2.15% | +20.25% |
Apr. 08 | HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA | CI |
Mar. 14 | Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024 |
Sales 2024 * | 64.08M 87.68M | Sales 2025 * | 73.43M 100M | Capitalization | 111M 151M |
---|---|---|---|---|---|
Net income 2024 * | -20M -27.37M | Net income 2025 * | -17M -23.26M | EV / Sales 2024 * | 1.73 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.51 x |
P/E ratio 2024 * |
-6.47
x | P/E ratio 2025 * |
-9.64
x | Employees | 91 |
Yield 2024 * |
4.26% | Yield 2025 * |
-
| Free-Float | 99.51% |
Latest transcript on HLS Therapeutics Inc.
1 day | +2.15% | ||
1 week | +2.15% | ||
Current month | +2.15% | ||
1 month | +10.47% | ||
3 months | +14.46% | ||
6 months | -4.04% | ||
Current year | +20.25% |
Managers | Title | Age | Since |
---|---|---|---|
Craig Millian
CEO | Chief Executive Officer | 56 | 23-04-30 |
John Hanna
DFI | Director of Finance/CFO | - | 23-06-21 |
Ryan Lennox
CMP | Compliance Officer | 43 | 18-05-06 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Welborn
CHM | Chairman | 46 | 21-06-17 |
Laura Brege
BRD | Director/Board Member | 66 | 19-03-20 |
John Hanna
DFI | Director of Finance/CFO | - | 23-06-21 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 4.75 | +2.15% | 1,900 |
24-05-02 | 4.65 | 0.00% | 468 |
24-04-30 | 4.65 | 0.00% | 5,000 |
24-04-26 | 4.65 | -1.69% | 700 |
Delayed Quote Toronto S.E., May 03, 2024 at 02:06 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.25% | 111M | |
+14.23% | 69.5B | |
+7.11% | 8.2B | |
-20.55% | 7.97B | |
-4.06% | 7.84B | |
+2.26% | 4.66B | |
+17.12% | 4.32B | |
+1.41% | 4.19B | |
-3.02% | 3.89B | |
+21.42% | 3.62B |
- Stock Market
- Equities
- HLS Stock